organization · Reporting owner
Pontifax Late Stage Fund L.P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 89bio, Inc.ETNB · Entity 73682 | 10% owner | November 11, 2019 | November 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
89bio, Inc.
Report date November 11, 2019 · Filed November 14, 2019
Jointly reported with Kariv Tomer, Pontifax (Israel) V, L.P., Pontifax (Cayman) V, L.P., Pontifax (China) V, L.P., Pontifax 5 G.P. L.P., Pontifax Management 4 G.P. (2015) Ltd., Pontifax Late Stage GP Ltd.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 250,000 |
Reported balance
After 2019-11-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-11-11 · Purchase · Acquired 250,000 · Balance 250,000 F1: On November 11, 2019, Pontifax (Israel) V, L.P. purchased 134,390 shares of the Issuer's common stock, Pontifax (Cayman) V, L.P. purchased 35,897 shares of the Issuer's common stock, Pontifax (China) V, L.P. (collectively, the "Pontifax Entities") purchased 52,213 shares of the Issuer's common stock and Pontifax Late Stage Fund L.P. ("Late Stage L.P.") purchased 27,500 shares of the Issuer's common stock at a price of $16.00 per share in the Issuer's initial public offering. F3: Includes (a) 134,390 shares held by Pontifax (Israel) V, L.P., (b) 35,897 shares held by Pontifax (Cayman) V, L.P., (c) 52,213 shares held by Pontifax (China) V, L.P. and (d) 27,500 shares held by Late Stage L.P. F6: Pontifax 5 G.P. L.P. ("Pontifax 5 GP") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. ("Pontifax Management") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage L.P. F7: (Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 1,134,671 |
Reported balance
After 2019-11-13 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-11-13 · Conversion · Acquired 884,671 · Balance 1,134,671 F2: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F4: Includes (a) 668,732 shares held by Pontifax (Israel) V, L.P., (b) 178,623 shares held by Pontifax (Cayman) V, L.P., (c) 259,816 shares held by Pontifax (China) V, L.P. and (d) 27,500 shares held by Late Stage L.P. F6: Pontifax 5 G.P. L.P. ("Pontifax 5 GP") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. ("Pontifax Management") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage L.P. F7: (Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2019-11-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-13 · Conversion · Disposed 5,500,001 · Balance 0 F2: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F5: Includes (a) 534,342 shares held by Pontifax (Israel) V, L.P., (b) 142,726 shares held by Pontifax (Cayman) V, L.P. and (c) 207,603 shares held by Pontifax (China) V, L.P. F6: Pontifax 5 G.P. L.P. ("Pontifax 5 GP") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. ("Pontifax Management") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage L.P. F7: (Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 11, 2019, Pontifax (Israel) V, L.P. purchased 134,390 shares of the Issuer's common stock, Pontifax (Cayman) V, L.P. purchased 35,897 shares of the Issuer's common stock, Pontifax (China) V, L.P. (collectively, the "Pontifax Entities") purchased 52,213 shares of the Issuer's common stock and Pontifax Late Stage Fund L.P. ("Late Stage L.P.") purchased 27,500 shares of the Issuer's common stock at a price of $16.00 per share in the Issuer's initial public offering.
F2: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date.
F3: Includes (a) 134,390 shares held by Pontifax (Israel) V, L.P., (b) 35,897 shares held by Pontifax (Cayman) V, L.P., (c) 52,213 shares held by Pontifax (China) V, L.P. and (d) 27,500 shares held by Late Stage L.P.
F4: Includes (a) 668,732 shares held by Pontifax (Israel) V, L.P., (b) 178,623 shares held by Pontifax (Cayman) V, L.P., (c) 259,816 shares held by Pontifax (China) V, L.P. and (d) 27,500 shares held by Late Stage L.P.
F5: Includes (a) 534,342 shares held by Pontifax (Israel) V, L.P., (b) 142,726 shares held by Pontifax (Cayman) V, L.P. and (c) 207,603 shares held by Pontifax (China) V, L.P.
F6: Pontifax 5 G.P. L.P. ("Pontifax 5 GP") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. ("Pontifax Management") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage L.P.
F7: (Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Keros Therapeutics, Inc.
Report date October 15, 2025 · Filed October 17, 2025
Jointly reported with Pontifax Management 4 G.P. (2015) Ltd., Pontifax (Israel) IV, L.P., Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P., Pontifax Late Stage GP Ltd., Kariv Tomer, Nussbaum Ran
Section 16 reporting ended · disclosed 2025-10-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | IndirectBy Pontifax (Israel) IV, L.P. | 0 |
Reported balance
After 2025-10-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-10-15 · Sale · Disposed 2,284,612 · Balance 0 F1: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Israel IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. |
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | IndirectBy Pontifax (Cayman) IV, L.P. | 0 |
Reported balance
After 2025-10-15 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-10-15 · Sale · Disposed 1,121,045 · Balance 0 F2: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. |
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | IndirectBy Pontifax (China) IV, L.P. | 0 |
Reported balance
After 2025-10-15 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-10-15 · Sale · Disposed 1,226,412 · Balance 0 F3: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by China IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. |
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | IndirectBy Pontifax Late Stage Fund, L.P. | 0 |
Reported balance
After 2025-10-15 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2025-10-15 · Sale · Disposed 155,262 · Balance 0 F4: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to the Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 and Tomer Kariv and Ran Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of his or its pecuniary interest therein. |
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | IndirectBy Tomer Kariv | 5,250 |
Reported balance
Holding disclosure · report date 2025-10-15 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 5,250 F5: In connection with the Stock Purchase Agreement, dated October 15, 2025, by and among certain of the Reporting Persons and the Issuer and the resignations of each of Tomer Kariv and Ran Nussbaum from the Issuer's board of directors, the Issuer accelerated the vesting of the restricted stock unit awards and certain options held by Messrs. Kariv and Nussbaum that were previously reported in their respective Form 4 filings. |
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | IndirectBy Ran Nussbaum | 5,250 |
Reported balance
Holding disclosure · report date 2025-10-15 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,250 F5: In connection with the Stock Purchase Agreement, dated October 15, 2025, by and among certain of the Reporting Persons and the Issuer and the resignations of each of Tomer Kariv and Ran Nussbaum from the Issuer's board of directors, the Issuer accelerated the vesting of the restricted stock unit awards and certain options held by Messrs. Kariv and Nussbaum that were previously reported in their respective Form 4 filings. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Israel IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
F2: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
F3: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by China IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
F4: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to the Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 and Tomer Kariv and Ran Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of his or its pecuniary interest therein.
F5: In connection with the Stock Purchase Agreement, dated October 15, 2025, by and among certain of the Reporting Persons and the Issuer and the resignations of each of Tomer Kariv and Ran Nussbaum from the Issuer's board of directors, the Issuer accelerated the vesting of the restricted stock unit awards and certain options held by Messrs. Kariv and Nussbaum that were previously reported in their respective Form 4 filings.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2025 Filed Oct 17, 2025 21:53 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock, $0.0001 par value per share | 155,262 | $17.75 | $2,755,900.50 |
DisclosureSEC source: 0000921895-25-002765 · form414601002_10172025.xml · nonDerivative · entry 4 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Kariv Tomer · CIK 0001568077 · Director · 10% owner Nussbaum Ran · CIK 0001609805 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Pontifax Late Stage Fund, L.P. Disclosed balance after: 0 F4 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to the Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 and Tomer Kariv and Ran Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 21:53 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock, $0.0001 par value per share | 1,226,412 | $17.75 | $21,768,813.00 |
DisclosureSEC source: 0000921895-25-002765 · form414601002_10172025.xml · nonDerivative · entry 3 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Kariv Tomer · CIK 0001568077 · Director · 10% owner Nussbaum Ran · CIK 0001609805 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Pontifax (China) IV, L.P. Disclosed balance after: 0 F3 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by China IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 21:53 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock, $0.0001 par value per share | 1,121,045 | $17.75 | $19,898,548.75 |
DisclosureSEC source: 0000921895-25-002765 · form414601002_10172025.xml · nonDerivative · entry 2 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Kariv Tomer · CIK 0001568077 · Director · 10% owner Nussbaum Ran · CIK 0001609805 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Pontifax (Cayman) IV, L.P. Disclosed balance after: 0 F2 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 21:53 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock, $0.0001 par value per share | 2,284,612 | $17.75 | $40,551,863.00 |
DisclosureSEC source: 0000921895-25-002765 · form414601002_10172025.xml · nonDerivative · entry 1 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Kariv Tomer · CIK 0001568077 · Director · 10% owner Nussbaum Ran · CIK 0001609805 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Pontifax (Israel) IV, L.P. Disclosed balance after: 0 F1 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Israel IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Read SEC document |
| November 29, 2022 Filed Nov 30, 2022 21:42 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherCall Options (obligation to sell) · Derivative | 1,914 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-059053 · doc4.xml · derivative · entry 6 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,914 shares Expires 2023-10-07 F1 · kind: Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. ("Israel IV"), Pontifax (Cayman) IV, L.P. ("Cayman IV") and Pontifax (China) IV, L.P. ("China IV") and a certain securityholder. F5 · derivative.exercise_date: Fully vested and exercisable. F4 · ownership.nature: The securities are held by China IV. Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 29, 2022 Filed Nov 30, 2022 21:42 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherCall Options (obligation to sell) · Derivative | 1,723 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-059053 · doc4.xml · derivative · entry 5 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,723 shares Expires 2023-10-07 F1 · kind: Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. ("Israel IV"), Pontifax (Cayman) IV, L.P. ("Cayman IV") and Pontifax (China) IV, L.P. ("China IV") and a certain securityholder. F5 · derivative.exercise_date: Fully vested and exercisable. F3 · ownership.nature: The securities are held by Cayman IV. Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 29, 2022 Filed Nov 30, 2022 21:42 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherCall Options (obligation to sell) · Derivative | 3,539 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-059053 · doc4.xml · derivative · entry 4 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,539 shares Expires 2023-10-07 F1 · kind: Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. ("Israel IV"), Pontifax (Cayman) IV, L.P. ("Cayman IV") and Pontifax (China) IV, L.P. ("China IV") and a certain securityholder. F5 · derivative.exercise_date: Fully vested and exercisable. F2 · ownership.nature: The securities are held by Israel IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 29, 2022 Filed Nov 30, 2022 21:42 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherCommon Stock | 1,914 | $0.00 | $0.19 |
DisclosureSEC source: 0001209191-22-059053 · doc4.xml · nonDerivative · entry 3 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,226,412 F1 · kind: Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. ("Israel IV"), Pontifax (Cayman) IV, L.P. ("Cayman IV") and Pontifax (China) IV, L.P. ("China IV") and a certain securityholder. F4 · ownership.nature: The securities are held by China IV. Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 29, 2022 Filed Nov 30, 2022 21:42 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherCommon Stock | 1,723 | $0.00 | $0.17 |
DisclosureSEC source: 0001209191-22-059053 · doc4.xml · nonDerivative · entry 2 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,121,045 F1 · kind: Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. ("Israel IV"), Pontifax (Cayman) IV, L.P. ("Cayman IV") and Pontifax (China) IV, L.P. ("China IV") and a certain securityholder. F3 · ownership.nature: The securities are held by Cayman IV. Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 29, 2022 Filed Nov 30, 2022 21:42 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | OtherCommon Stock | 3,539 | $0.00 | $0.35 |
DisclosureSEC source: 0001209191-22-059053 · doc4.xml · nonDerivative · entry 1 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,284,612 F1 · kind: Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. ("Israel IV"), Pontifax (Cayman) IV, L.P. ("Cayman IV") and Pontifax (China) IV, L.P. ("China IV") and a certain securityholder. F2 · ownership.nature: The securities are held by Israel IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 21:38 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 6,000 | $50.00 | $300,000.00 |
DisclosureSEC source: 0001209191-20-059404 · doc4.xml · nonDerivative · entry 4 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 155,262 F4 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. F5 · ownership.nature: Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 21:38 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 14,400 | $50.00 | $720,000.00 |
DisclosureSEC source: 0001209191-20-059404 · doc4.xml · nonDerivative · entry 3 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,228,326 F3 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 21:38 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 12,966 | $50.00 | $648,300.00 |
DisclosureSEC source: 0001209191-20-059404 · doc4.xml · nonDerivative · entry 2 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,122,768 F2 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 21:38 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 26,634 | $50.00 | $1,331,700.00 |
DisclosureSEC source: 0001209191-20-059404 · doc4.xml · nonDerivative · entry 1 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,288,151 F1 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 6,000 | $50.00 | $300,000.00 |
DisclosureSEC source: 0001209191-20-059411 · doc4.xml · nonDerivative · entry 4 Nussbaum Ran · CIK 0001609805 · Director · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 155,262 F4 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. F5 · ownership.nature: Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 14,400 | $50.00 | $720,000.00 |
DisclosureSEC source: 0001209191-20-059411 · doc4.xml · nonDerivative · entry 3 Nussbaum Ran · CIK 0001609805 · Director · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,228,326 F3 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 12,966 | $50.00 | $648,300.00 |
DisclosureSEC source: 0001209191-20-059411 · doc4.xml · nonDerivative · entry 2 Nussbaum Ran · CIK 0001609805 · Director · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,122,768 F2 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 26,634 | $50.00 | $1,331,700.00 |
DisclosureSEC source: 0001209191-20-059411 · doc4.xml · nonDerivative · entry 1 Nussbaum Ran · CIK 0001609805 · Director · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,288,151 F1 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 6,000 | $50.00 | $300,000.00 |
DisclosureSEC source: 0001209191-20-059410 · doc4.xml · nonDerivative · entry 4 Kariv Tomer · CIK 0001568077 · Director · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 155,262 F4 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. F5 · ownership.nature: Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 14,400 | $50.00 | $720,000.00 |
DisclosureSEC source: 0001209191-20-059410 · doc4.xml · nonDerivative · entry 3 Kariv Tomer · CIK 0001568077 · Director · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,228,326 F3 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 12,966 | $50.00 | $648,300.00 |
DisclosureSEC source: 0001209191-20-059410 · doc4.xml · nonDerivative · entry 2 Kariv Tomer · CIK 0001568077 · Director · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,122,768 F2 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 26,634 | $50.00 | $1,331,700.00 |
DisclosureSEC source: 0001209191-20-059410 · doc4.xml · nonDerivative · entry 1 Kariv Tomer · CIK 0001568077 · Director · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,288,151 F1 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries C Preferred Stock · Derivative | 36,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · derivative · entry 26 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 36,858 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F5 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. F6 · ownership.nature: Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries C Preferred Stock · Derivative | 79,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · derivative · entry 25 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 79,653 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F4 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries C Preferred Stock · Derivative | 88,460 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · derivative · entry 24 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 88,460 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries C Preferred Stock · Derivative | 163,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · derivative · entry 23 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 163,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries B-1 Preferred Stock · Derivative | 68,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · derivative · entry 22 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 68,654 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F5 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. F6 · ownership.nature: Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries B-1 Preferred Stock · Derivative | 91,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · derivative · entry 21 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 91,538 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F4 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries B-1 Preferred Stock · Derivative | 82,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · derivative · entry 20 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 82,425 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries B-1 Preferred Stock · Derivative | 169,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · derivative · entry 19 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 169,307 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries A Preferred Stock · Derivative | 737,226 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · derivative · entry 18 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 737,226 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F4 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries A Preferred Stock · Derivative | 663,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · derivative · entry 17 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 663,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries A Preferred Stock · Derivative | 1,363,542 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · derivative · entry 16 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,363,542 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 43,750 | $16.00 | $700,000.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 15 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 149,262 F5 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. F6 · ownership.nature: Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 105,000 | $16.00 | $1,680,000.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 14 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,213,926 F4 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 94,546 | $16.00 | $1,512,736.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 13 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,109,802 F3 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 194,203 | $16.00 | $3,107,248.00 |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 12 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,261,517 F2 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 36,858 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 11 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 105,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F5 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. F6 · ownership.nature: Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 79,653 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 10 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,108,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F4 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 88,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 9 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,015,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 163,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 8 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,067,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 68,654 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 7 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 68,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F5 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. F6 · ownership.nature: Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 91,538 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 6 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,029,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F4 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 82,425 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 5 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 926,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 169,307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 4 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,903,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 737,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 3 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 937,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F4 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 663,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 2 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 844,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 21:18 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 1,363,542 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024231 · doc4.xml · nonDerivative · entry 1 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,734,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 00:10 UTC | 89bio, Inc. ETNB · Entity 73682 | ConversionSeries A Preferred Stock · Derivative | 5,500,001 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-027228 · doc4.xml · derivative · entry 3 Kariv Tomer · CIK 0001568077 · Director · 10% owner Pontifax (Israel) V, L.P. · CIK 0001792890 · 10% owner Pontifax (Cayman) V, L.P. · CIK 0001792893 · 10% owner Pontifax (China) V, L.P. · CIK 0001792891 · 10% owner Pontifax 5 G.P. L.P. · CIK 0001792892 · 10% owner Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 884,671 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F2 · derivative.exercise_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F2 · derivative.expiration_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F5 · ownership.nature: Includes (a) 534,342 shares held by Pontifax (Israel) V, L.P., (b) 142,726 shares held by Pontifax (Cayman) V, L.P. and (c) 207,603 shares held by Pontifax (China) V, L.P. F6 · ownership.nature: Pontifax 5 G.P. L.P. ("Pontifax 5 GP") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. ("Pontifax Management") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage L.P. F7 · ownership.nature: (Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 00:10 UTC | 89bio, Inc. ETNB · Entity 73682 | ConversionCommon Stock | 884,671 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-027228 · doc4.xml · nonDerivative · entry 2 Kariv Tomer · CIK 0001568077 · Director · 10% owner Pontifax (Israel) V, L.P. · CIK 0001792890 · 10% owner Pontifax (Cayman) V, L.P. · CIK 0001792893 · 10% owner Pontifax (China) V, L.P. · CIK 0001792891 · 10% owner Pontifax 5 G.P. L.P. · CIK 0001792892 · 10% owner Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 1,134,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F4 · ownership.nature: Includes (a) 668,732 shares held by Pontifax (Israel) V, L.P., (b) 178,623 shares held by Pontifax (Cayman) V, L.P., (c) 259,816 shares held by Pontifax (China) V, L.P. and (d) 27,500 shares held by Late Stage L.P. F6 · ownership.nature: Pontifax 5 G.P. L.P. ("Pontifax 5 GP") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. ("Pontifax Management") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage L.P. F7 · ownership.nature: (Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.